StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)

Close on Nov 17, 2026Market cap $792.02MP/E –Yield –

Lexicon Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Lexicon Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$54.02M. For fiscal 2025 it was -$48.29M. The highest annual figure on record is $145.10M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.29M–
FY2024Dec 31, 2024-$196.58M–
FY2023Dec 31, 2023-$171.20M–
FY2022Dec 31, 2022-$100.33M–
FY2021Dec 31, 2021-$86.80M–
FY2020Dec 31, 2020-$44.87M-130.9%
FY2019Dec 31, 2019$145.10M–
FY2018Dec 31, 2018-$99.60M–
FY2017Dec 31, 2017-$127.23M–
FY2016Dec 31, 2016-$125.12M-5800.0%
FY2015Dec 31, 2015$2.20M–
FY2014Dec 31, 2014-$98.44M–
FY2013Dec 31, 2013-$99.51M–
FY2012Dec 31, 2012-$104.23M–
FY2011Dec 31, 2011-$109.21M–
FY2010Dec 31, 2010-$90.32M–
FY2009Dec 31, 2009-$83.80M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.44M-775.8%
Q1 FY2026Mar 31, 2026-$886.00K–
Q4 FY2025Dec 31, 2025-$14.66M–
Q3 FY2025Sep 30, 2025-$12.04M–
Q2 FY2025Jun 30, 2025$3.91M–
Q1 FY2025Mar 31, 2025-$25.50M–
Q4 FY2024Dec 31, 2024-$32.61M–
Q3 FY2024Sep 30, 2024-$63.57M–
Q2 FY2024Jun 30, 2024-$55.22M–
Q1 FY2024Mar 31, 2024-$45.19M–
Q4 FY2023Dec 31, 2023-$46.59M–
Q3 FY2023Sep 30, 2023-$49.48M–
Q2 FY2023Jun 30, 2023-$44.10M–
Q1 FY2023Mar 31, 2023-$31.03M–
Q4 FY2022Dec 31, 2022-$30.18M–
Q3 FY2022Sep 30, 2022-$22.99M–
Q2 FY2022Jun 30, 2022-$23.90M–
Q1 FY2022Mar 31, 2022-$23.27M–
Q4 FY2021Dec 31, 2021-$25.22M–
Q3 FY2021Sep 30, 2021-$22.86M-126.1%
Q2 FY2021Jun 30, 2021-$17.92M–
Q1 FY2021Mar 31, 2021-$20.80M–
Q4 FY2020Dec 31, 2020-$7.11M–
Q3 FY2020Sep 30, 2020$87.46M-61.2%
Q2 FY2020Jun 30, 2020-$63.68M–
Q1 FY2020Mar 31, 2020-$61.53M–
Q4 FY2019Dec 31, 2019-$46.28M–
Q3 FY2019Sep 30, 2019$225.58M–
Q2 FY2019Jun 30, 2019-$17.64M–
Q1 FY2019Mar 31, 2019-$16.57M–
Q4 FY2018Dec 31, 2018-$11.46M–
Q3 FY2018Sep 30, 2018-$22.01M–
Q2 FY2018Jun 30, 2018-$29.34M–
Q1 FY2018Mar 31, 2018-$36.79M–
Q4 FY2017Dec 31, 2017-$28.09M–
Q3 FY2017Sep 30, 2017-$27.68M–
Q2 FY2017Jun 30, 2017-$32.57M–
Q1 FY2017Mar 31, 2017-$38.88M–
Q4 FY2016Dec 31, 2016-$30.82M–
Q3 FY2016Sep 30, 2016-$34.42M–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?